Lantern Pharma (LTRN) AI Stock Analysis

• Market Cap: $43.46M
• Dividend Yield: N/A
• Average Volume (3M): 242.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: N/A
• EPS Growth: -31.16%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 10,784,725
• 10 Day Avg. Volume: 604,071
• 30 Day Avg. Volume: 242,559
• PEG Ratio: -0.44
• Price to Book (P/B): 2.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.12
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 65.83
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: $25.00
• Price Target Upside: 491.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: ―

Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.

Lantern Pharma Business Overview & Revenue Model

Company Description

Lantern Pharma Inc. (LTRN) is a biotechnology company focused on leveraging artificial intelligence (AI), machine learning, and genomic data to streamline the drug development process in oncology. The company's mission is to improve the efficiency and success rate of cancer drug development by identifying and advancing promising drug candidates. Lantern Pharma operates in the healthcare and biotechnology sectors, developing precision medicine approaches for cancer treatment.

How the Company Makes Money

Lantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.

Lantern Pharma Financial Statement Overview

Summary

Lantern Pharma faces significant financial challenges, with zero revenue and increasing operational losses. Despite a strong balance sheet with low debt, the negative cash flow situation raises concerns about long-term viability and the need for additional financing.

Income Statement

Lantern Pharma has consistently reported zero revenue, indicating a pre-revenue stage or significant challenges in generating sales. The company's net losses have increased substantially over the years, reflecting mounting operational challenges. The EBIT and EBITDA margins are negative due to high operational expenses without corresponding revenue, undermining profitability prospects.

Balance Sheet

The company maintains a strong equity position relative to its assets, with a high equity ratio, reflecting financial stability. The debt-to-equity ratio is low, indicating minimal reliance on debt financing, which reduces financial risk. However, the consistent increase in liabilities and decreasing cash reserves could affect future liquidity and operational capacity.

Cash Flow

Lantern Pharma exhibits negative operating and free cash flows, indicating cash burn without revenue inflow. Despite substantial financing inflows in prior years, the inability to generate positive cash flows from operations is concerning. The lack of free cash flow growth highlights potential sustainability challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-174.84K	-154.68K	-97.42K	-3.39K
EBITDA	-20.59M	-15.79M	-14.42M	-12.27M	-5.90M
Net Income	-20.78B	-15.96M	-14.09M	-12.30M	-5.91M
Balance Sheet
Total Assets	25.57M	43.65M	58.84M	73.95M	20.36M
Cash, Cash Equivalents and Short-Term Investments	24.01M	41.30M	55.20M	70.73M	19.23M
Total Debt	243.66K	234.47K	52.89K	204.95K	108.50K
Total Liabilities	4.38M	2.74M	2.80M	2.38M	660.84K
Stockholders Equity	21.19B	40.91M	56.04M	71.57M	19.70M
Cash Flow
Free Cash Flow	-17.83M	-14.37M	-12.80M	-10.61M	-5.67M
Operating Cash Flow	-17.81M	-14.35M	-12.77M	-10.59M	-5.65M
Investing Cash Flow	3.37M	-930.21K	179.27K	-19.53M	-16.14K
Financing Cash Flow	66.71K	-500.00K	―	63.42M	23.66M

Lantern Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Positive. The current price of 4.23 is above the 20-day moving average (MA) of 3.58, above the 50-day MA of 3.44, and above the 200-day MA of 3.64, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 63.37 is Neutral, neither overbought nor oversold. The STOCH value of 64.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LTRN.

Lantern Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥351.06B	11.13	-2.99%	2.50%	11.77%	-10.16%
LTRN	45 Neutral	$43.46M	―	-75.66%	―	―	-31.16%
HOWL	45 Neutral	$62.82M	―	-82.81%	―	-92.95%	-50.02%
APLT	39 Underperform	$67.23M	―	-83.71%	―	―	―
OKYO	38 Underperform	$103.43M	―	0.00%	―	―	―
FBRX	36 Underperform	$129.96M	―	-130.27%	―	―	43.64%
ANTX	34 Underperform	$33.50M	―	-49.32%	―	―	38.98%

Lantern Pharma Corporate Events

Lantern Pharma Reports Q4 2024 Financial Results and AI Progress

On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.